
Please try another search
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.
Name | Age | Since | Title |
---|---|---|---|
Debra Stephanie Barker | 63 | 2019 | Independent Non-Executive Director |
John Heymach | - | 2023 | Member of Scientific Advisory Board |
Sally Louise Bennett | 53 | 2020 | Independent Non-Executive Director |
Anders Lennart Tullgren | 64 | 2022 | Independent Chairman of the Board |
Shu Kam Mok | 65 | 2023 | Member of Scientific Advisory Board |
Enriqueta Felip Font | 61 | 2023 | Member of Scientific Advisory Board |
Solange Peters | 53 | 2023 | Member Scientific Advisory Board |
David Colpman | 64 | 2024 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review